Maxheal Pharmaceuticals (india) Limited

Maxheal Pharmaceuticals (India) Limited, established in 1984, is a prominent pharmaceutical manufacturer and exporter based in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its product portfolio encompasses a wide range of therapeutic categories such as antibiotics, anti-inflammatory agents, and central nervous system (CNS) drugs. Maxheal Pharmaceuticals is recognized for its commitment to quality and innovation, adhering to international standards in its manufacturing processes.

The company's Corporate Identification Number (CIN) is U73100MH2009PLC193624, and it is registered under the Registrar of Companies, Mumbai. Maxheal Pharmaceuticals operates as a public limited company with an authorized capital of ₹4.00 crore and a paid-up capital of ₹1.00 crore. As of the latest available data, the company employs approximately 67 professionals. The registered office is located at 301, 3rd Floor, Maxheal House, Plot No. CST No. 1043, Bangur Nagar, Goregaon (West), Mumbai, Maharashtra, 400090.

Maxheal Pharmaceuticals operates multiple manufacturing facilities across India, each specializing in different product lines to meet diverse market demands. The company's flagship plant is situated in Nashik, Maharashtra, approximately 180 km from Mumbai. This facility is dedicated to the production of β-lactam antibiotics, including penicillins and cephalosporins, and is certified by the European Union's Good Manufacturing Practice (EU-GMP). The Nashik plant has an annual manufacturing capacity of 750 million tablets, 900 million capsules, and 5.4 million dry syrup bottles.

In addition to the Nashik plant, Maxheal Pharmaceuticals has a WHO-cGMP-certified unit in Boisar, Maharashtra, acquired from Ally Pharma Options Pvt. Ltd. This facility is approved by regulatory bodies such as NAFDAC, FDB (Ghana), Kenya, and Uganda. The Boisar plant spans 8,361 square meters, with 4,089 square meters of constructed area and an additional 4,022 square meters allocated for future expansion. This strategic location and infrastructure enable Maxheal Pharmaceuticals to cater to both domestic and international markets effectively.

Maxheal Pharmaceuticals is led by a team of experienced professionals committed to driving the company's growth and maintaining its reputation for quality. The Managing Director is Mr. Mehul Madan Sakhala, who holds a Master's degree in Management and International Business from the UK. Under his leadership, the company has implemented ultramodern technological advancements and aligned operations towards environmental sustainability.

The Board of Directors includes Mr. Madanlal Mohanlal Sakhala and Mrs. Hemlata Madanlal Sakhala, who have been instrumental in the company's strategic direction and expansion. Their combined expertise and vision have been pivotal in establishing Maxheal Pharmaceuticals as a leader in the pharmaceutical manufacturing sector.

Maxheal Pharmaceuticals has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's commitment to quality is evident through its adherence to international standards, as demonstrated by its EU-GMP certification for the Nashik plant. This certification facilitates access to European markets, ensuring that Maxheal Pharmaceuticals' products meet stringent quality requirements.

While specific details regarding regulatory filings and approvals in the United States, United Kingdom, Australia, and Japan are not publicly disclosed, the company's WHO-cGMP certification for the Boisar plant indicates compliance with global manufacturing standards. This certification is recognized by various international regulatory bodies, enhancing the company's credibility and potential for market access in these regions.

Maxheal Pharmaceuticals has strategically positioned itself to penetrate emerging markets in Africa, Latin America, and Southeast Asia. The WHO-cGMP certification of its manufacturing facilities, particularly the Boisar plant, plays a crucial role in this expansion. This certification is recognized by regulatory authorities in several countries, including those in Africa and Southeast Asia, facilitating smoother market entry and acceptance.

The company's focus on quality and compliance with international standards enhances its competitiveness in these regions, where there is a growing demand for affordable and effective pharmaceutical products. By leveraging its manufacturing capabilities and certifications, Maxheal Pharmaceuticals aims to establish a strong foothold in these emerging markets, contributing to improved healthcare outcomes.

Maxheal Pharmaceuticals demonstrates a diversified geographic strategy, balancing its presence across both regulated and emerging markets. The company's adherence to international manufacturing standards, as evidenced by its EU-GMP and WHO-cGMP certifications, mitigates concentration risks associated with reliance on a single market. This strategic diversification allows Maxheal Pharmaceuticals to leverage growth opportunities globally while maintaining operational stability.

The company's expansion into emerging markets, supported by its certifications and quality assurance measures, reflects a proactive approach to global market penetration. This strategy not only enhances revenue streams but also positions Maxheal Pharmaceuticals as a competitive player in the global pharmaceutical industry.

Specific details regarding Maxheal Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly disclosed. The company's adherence to international manufacturing standards, such as EU-GMP and WHO-cGMP certifications, indicates a commitment to quality that aligns with FDA expectations. However, without explicit FDA approvals or registrations, the company's direct market access in the United States remains unverified.

Maxheal Pharmaceuticals' manufacturing facilities, particularly the Nashik plant, are certified by the European Union's Good Manufacturing Practice (EU-GMP). This certification ensures that the company's products meet stringent quality standards required for the European market. Additionally, the Boisar plant holds WHO-cGMP certification, recognized by various international regulatory bodies, facilitating market access in regions that acknowledge this certification.

Maxheal Pharmaceuticals operates in compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations in India. The company's manufacturing facilities are licensed by the CDSCO, ensuring adherence to national standards for pharmaceutical manufacturing. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's WHO-cGMP and EU-GMP certifications suggest a robust compliance framework that likely aligns with CDSCO requirements.

As of the latest available information, there are no publicly disclosed records of Form 483 observations, warning letters, or import alerts issued to Maxheal Pharmaceuticals by regulatory authorities. The company's adherence to international manufacturing standards, such as EU-GMP and WHO-cGMP certifications, indicates a proactive approach to compliance and quality assurance. This commitment likely contributes to a positive regulatory standing and minimizes the risk of enforcement actions.

Maxheal Pharmaceuticals operates in a competitive landscape, with several key players in the Indian pharmaceutical manufacturing sector. While specific market share data is not publicly available, the company's focus on high-quality finished pharmaceutical formulations positions it favorably against competitors. The adherence to international manufacturing standards, such as EU-GMP and WHO-cGMP certifications, enhances its credibility and appeal in both domestic and international markets.

The company's strategic diversification into emerging markets further strengthens its competitive position, allowing it to tap into growing demand for affordable and effective pharmaceutical products. By leveraging its manufacturing capabilities and certifications, Maxheal Pharmaceuticals aims to establish a strong foothold in these regions, contributing to improved healthcare outcomes.

Maxheal Pharmaceuticals distinguishes itself through its commitment to quality and innovation. The company's adherence to international manufacturing standards, as evidenced by its EU-GMP and WHO-cGMP certifications, ensures that its products meet stringent quality requirements. This focus on quality is further supported by its dedicated research and development efforts, leading to a diverse product portfolio that addresses various therapeutic areas.

Additionally, the company's strategic diversification into both regulated and emerging markets demonstrates a proactive approach to global expansion. By leveraging its manufacturing capabilities and certifications, Maxheal Pharmaceuticals aims to establish a strong foothold in